Novartis Ag's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 7.89, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Novartis Ag in Dec 31 2025 quarter, has decreased to 46 days, compared to 48 days, in the 0 quarter.

If we take a look into Healthcare sector 514 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from to 3648.

What is Receivable Turnover Ratio?
What is Novartis Ag Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NVS Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Receivable Change	20.4 %	20.4 %	10.06 %	20.4 %	4.45 %
Y / Y Revenue Change	9.57 %	-	12.32 %	-	10.85 %
Receivable Turnover Ratio (TTM)	7.89	7.66	8.01	8.03	8.42
NVS's Total Ranking	# 3648	#	#	#	# 3909
Accounts Receivable average collection period days	46	48	46	45	43
Seq. Receivable Change	0 %	-1.31 %	1.33 %	20.4 %	0 %
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 170
Healthcare Sector	# 515
Overall Market	# 3648

Receivable Turnover Ratio Statistics
High	Average	Low
3.93	3.54	3.25
(Dec 31 2024)		(Dec 31 2020)

NVS Company Profile • Back to NVS Efficiency Comparisons • Compare NVS Receivables Turnover Ratio to its Competitors

Financial Statements
Novartis Ag's Accounts Receivable	$ 8,937 Millions	Visit NVS's Balance sheet
Novartis Ag's Sales TTM	$ 70,725 Millions	Visit NVS's Income Statement
Sources of NVS's Revenues		Visit NVS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NVS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NVS's Growth Rates	NVS's Roa	NVS's Inventory Turnover Ratio	NVS's Dividend Comparisons
NVS's Profitability Ratios	NVS's Roi	NVS's Asset Turnover Ratio	NVS's Dividend Growth
NVS's Valuation Ratios	NVS's Roe	NVS's Financial Strength Ratios	NVS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Telix Pharmaceuticals Ltd	21.68	$ 803.794 Millions	$ 37.080 Millions
Lifemd Inc	21.48	$ 193.686 Millions	$ 9.018 Millions
Fonar Corporation	21.42	$ 106.031 Millions	$ 4.950 Millions
Neuraxis Inc	21.11	$ 3.569 Millions	$ 0.169 Millions
Biorestorative Therapies Inc	20.88	$ 0.360 Millions	$ 0.017 Millions
Arvinas Inc	19.93	$ 262.600 Millions	$ 13.175 Millions
Voyager Therapeutics Inc	19.59	$ 40.374 Millions	$ 2.061 Millions
Sonida Senior Living Inc	19.55	$ 381.141 Millions	$ 19.494 Millions
Siga Technologies Inc	19.47	$ 94.575 Millions	$ 4.856 Millions
Kiniksa Pharmaceuticals International Plc	19.45	$ 677.564 Millions	$ 34.828 Millions
Lipocine Inc	18.38	$ 1.977 Millions	$ 0.108 Millions
Wave Life Sciences Ltd	18.34	$ 59.102 Millions	$ 3.223 Millions
Vystar Corporation	18.31	$ 0.055 Millions	$ 0.003 Millions
Euda Health Holdings Limited	18.26	$ 5.993 Millions	$ 0.328 Millions
Nurix Therapeutics Inc	17.68	$ 83.980 Millions	$ 4.750 Millions
Marpai Inc	16.64	$ 18.099 Millions	$ 1.088 Millions
Bioage Labs Inc	16.01	$ 8.995 Millions	$ 0.562 Millions
Nutriband Inc	15.64	$ 2.037 Millions	$ 0.130 Millions
Plus Therapeutics Inc	15.53	$ 5.213 Millions	$ 0.336 Millions
Talkspace Inc	15.35	$ 228.871 Millions	$ 14.915 Millions
Nanobiotix S a	15.26	$ 36.504 Millions	$ 2.392 Millions
Gsk Plc	15.21	$ 32,667.000 Millions	$ 2,148.000 Millions
Precipio inc	15.02	$ 24.049 Millions	$ 1.601 Millions
Qhslab Inc	14.47	$ 2.692 Millions	$ 0.186 Millions
Arbutus Biopharma Corp	14.04	$ 14.083 Millions	$ 1.003 Millions
Sutro Biopharma Inc	13.92	$ 102.484 Millions	$ 7.365 Millions
Aim Immunotech Inc	13.54	$ 0.088 Millions	$ 0.007 Millions
Amneal Pharmaceuticals Inc	13.44	$ 3,018.308 Millions	$ 224.629 Millions
Inmed Pharmaceuticals Inc	13.26	$ 4.507 Millions	$ 0.340 Millions
Rosecliff Acquisition Corp I	13.19	$ 20.547 Millions	$ 1.557 Millions

Date modified: 2026-09-08T15:11:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.